Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NW-301V
- Development stage
- Phase 1
- Lead developer
- Neowise Biotechnology
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
NW-301V is an autologous T-cell therapy in which a patient's own T cells are genetically engineered to express a specific T cell receptor (TCR) that targets tumor cells harboring the KRAS G12V mutation. This therapy is designed for the treatment of advanced solid tumors, including pancreatic cancer, lung adenocarcinoma, and colorectal cancer. The mechanism of action involves the recognition and targeting of KRAS G12V mutant tumor cells by the modified TCR-T cells, leading to selective immune-mediated destruction of these cancerous cells. NW-301V is currently in Phase 1 clinical trials and is administered via parenteral route[3][4][5].
- Other names
- TCR-T T cell targeting KRAS G12V mutation
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on NW-301V.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NW-301V.